featured
Duvelisib Following Progression on Ofatumumab for Relapsed/Refractory CLL or Small Lymphocytic Lymphoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Clinical Cancer Research
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients With Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study
Clin. Cancer Res 2020 Jan 21;[EPub Ahead of Print], MS Davids, BJ Kuss, P Hillmen, M Montillo, C Moreno, J Essell, N Lamanna, Z Nagy, CS Tam, S Stilgenbauer, P Ghia, J Delgado, S Lustgarten, DT Weaver, H Youssoufian, U JägerFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.